Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

131.34 +0.75 (+0.57%)
Streaming Delayed Price Updated: 9:57 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
44 45 Next >
News headline image
2 Sweet Dividend Stocks to Buy to Satisfy Your Craving for Passive Income ↗
Dividend stocks can strengthen your portfolio during any market environment. 
Via The Motley Fool
News headline image
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever. ↗
These stocks pay income that investors can count on over the long run. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Healthcare Sector Navigates Mixed Market Close: A Beacon of Stability Amidst Uncertainty
As the broader market concluded with a mixed performance on November 14, 2025, the S&P 500 Healthcare sector once again underscored its often-defensive nature, demonstrating resilience amidst an... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
What Does the Market Think About Abbott Laboratories? ↗
 
Via Benzinga
News headline image
Chicago Fed's 7th District Hiring Expectations Crash to -40: A Dire Signal for the Economy and Fed Policy
The economic outlook for the U.S. Midwest has taken a concerning turn as the Chicago Federal Reserve's 7th District hiring expectations index reportedly plummeted to -40 in October 2025. This alarming... 
Via MarketMinute
Topics Artificial Intelligence Economy Immigration
News headline image
2 Top Dividend Stocks to Buy and Hold Forever ↗
These companies have already handsomely rewarded longtime shareholders, and it's not too late to join the party. 
Via The Motley Fool
News headline image
Corporate Earnings Fuel Market Gains, But Mixed Results Hint at Underlying Volatility
Recent third-quarter (Q3) 2025 corporate earnings have painted a complex yet largely positive picture for North American equity markets. While robust performances from key sectors, particularly... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Q3 Earnings Outperformers: Abbott Laboratories (NYSE:ABT) And The Rest Of The Medical Devices & Supplies - Diversified Stocks
Looking back on medical devices & supplies - diversified stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Abbott Laboratories (NYSE:ABT) and its peers. 
Via StockStory
News headline image
Economic Crossroads: How Key Indicators Are Steering the Stock Market Through Moderation and Policy Shifts
The financial markets are currently navigating a complex and often contradictory economic landscape, heavily influenced by a suite of critical indicators such as jobs data and the Purchasing Managers'... 
Via MarketMinute
Topics Artificial Intelligence Economy Immigration
News headline image
AI's Power Problem ↗
AIs are hungry and growing more insatiable by the day. Will we be able to sustainably generate the power needed to feed the AI beast? 
Via The Motley Fool
Topics Artificial Intelligence Economy Energy
News headline image
ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat ↗
Via MarketBeat
News headline image
Dexcom Stock, Down 13%, Haunted By Its 'Surprisingly Cautious' Outlook ↗
Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled. 
Via Investor's Business Daily
News headline image
Should You Buy DexCom Stock Before Oct. 31? ↗
The company hasn't had a great year. Is it about to turn things around? 
Via The Motley Fool
Topics Lawsuit
News headline image
Recent Corporate Earnings Fuel Market Rally to Record Highs: AI and Rate Cut Hopes Drive Optimism
The third-quarter (Q3) 2025 earnings season has delivered a powerful jolt to global financial markets, propelling major U.S. indices to unprecedented record highs. A wave of surprisingly robust... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Is the Market Bullish or Bearish on Abbott Laboratories? ↗
 
Via Benzinga
News headline image
Billionaire Israel "Izzy" Englander Has Loaded Up on This Dividend King. Should You? ↗
Englander seems to have had several good reasons to aggressively buy shares of this big drugmaker. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Abbott Laboratories (NYSE:ABT): A Strong Dividend Stock for Reliable Income and Growth ↗
Discover Abbott Laboratories (ABT), a top dividend stock with a 1.87% yield, 11% growth, and a strong financial profile for reliable income. 
Via Chartmill
News headline image
Integer Holdings (ITGR) Shares Plunge 31.4% as Slower New Product Adoption and Revised Guidance Rock Investor Confidence
New York, NY – October 23, 2025 – Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract manufacturer, experienced a dramatic downturn in its stock performance today, with shares... 
Via MarketMinute
Topics Earnings Supply Chain
News headline image
EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards ↗
Trinity Capital Inc. announced a financing agreement with Bobbie, an organic infant nutrition company, to boost production capacity and ensure wider distribution of its products. 
Via Benzinga
News headline image
1 Safe-and-Steady Stock with Exciting Potential and 2 We Question
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
A Look Into Abbott Laboratories Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Boston Scientific Soars: Q3 2025 Earnings Beat Ignites Medical Device Market
Boston Scientific (NYSE: BSX) has delivered an exceptional third-quarter 2025 earnings report, significantly surpassing analyst expectations and reinforcing its position as a leading innovator in the... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
The 5 Most Interesting Analyst Questions From Abbott Laboratories’s Q3 Earnings Call
Abbott Laboratories’ third quarter results met Wall Street’s expectations for both revenue and non-GAAP profit, but the market reacted negatively, with shares declining over 4%. Management pointed to... 
Via StockStory
Topics Earnings
News headline image
U.S. Job Growth Stalls at 0.1%: Echoes of 2009 as Economy Navigates Fragile Labor Market
The U.S. economy is currently grappling with a significant deceleration in job growth, with proprietary data from investment giant Vanguard revealing a meager 0.1% growth rate for seven of the first... 
Via MarketMinute
Topics Artificial Intelligence Economy Immigration
News headline image
Abbott Laboratories' October Price Plunge Is a Signal to Buy ↗
Abbott Laboratories is on track to reach new highs, potentially by early 2026, opening the door for a 30% stock price increase in addition to the dividend. 
Via MarketBeat
News headline image
Earnings Season Fuels Market Optimism Amidst Economic Headwinds
As the Q3 2025 earnings season unfolds, corporate America is delivering a powerful narrative of resilience and growth, significantly influencing overall stock market movements. Despite a complex... 
Via MarketMinute
Topics Artificial Intelligence Economy Workforce
News headline image
Analyst See Noise In Q3 P&L, Affirms Abbott's Medtech Strength ↗
Abbott eyes 10% EPS growth in 2026 with CGM momentum, new nutrition contracts, and medical device launches driving global expansion. 
Via Benzinga
News headline image
These Analysts Revise Their Forecasts On Abbott Following Q3 Results ↗
 
Via Benzinga
News headline image
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever. ↗
Investors should be able to count on these stocks to deliver steady and growing income over the long term. 
Via The Motley Fool
News headline image
ABT Q3 Deep Dive: Q3 Results in Line with Expectations, Product Pipeline and Market Dynamics Shape Outlook
Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 6.9% year on year to $11.37 billion. Its non-GAAP profit of $1.30... 
Via StockStory
Topics World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
44 45 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.